Total Payments
$400,302
2024 Payments
$22,878
Companies
6
Transactions
180
Payment Breakdown by Category
Research$367,482 (91.8%)
Consulting$32,820 (8.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $367,482 | 128 | 91.8% |
| Consulting Fee | $32,820 | 52 | 8.2% |
Payments by Type
Research
$367,482
128 transactions
General
$32,820
52 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $246,778 | 80 | $0 (2024) |
| Eli Lilly and Company | $82,394 | 23 | $0 (2024) |
| PFIZER INC. | $32,820 | 52 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $19,620 | 9 | $0 (2018) |
| Regeneron Pharmaceuticals, Inc. | $14,865 | 11 | $0 (2018) |
| Celltrion, Inc. | $3,825 | 5 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,878 | 13 | Novartis Pharmaceuticals Corporation ($19,483) |
| 2023 | $45,030 | 9 | Novartis Pharmaceuticals Corporation ($41,520) |
| 2022 | $28,770 | 10 | Novartis Pharmaceuticals Corporation ($15,450) |
| 2021 | $34,666 | 15 | Novartis Pharmaceuticals Corporation ($25,950) |
| 2020 | $34,725 | 10 | Novartis Pharmaceuticals Corporation ($34,725) |
| 2019 | $55,800 | 14 | Novartis Pharmaceuticals Corporation ($47,850) |
| 2018 | $76,530 | 69 | NOVARTIS PHARMACEUTICALS CORPORATION ($36,128) |
| 2017 | $101,903 | 40 | Eli Lilly and Company ($42,630) |
All Payment Transactions
180 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $825.00 | Research |
| Study: PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | ||||||
| 08/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $450.00 | Research |
| Study: EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY | ||||||
| 08/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $185.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | ||||||
| 08/27/2024 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $75.00 | General |
| 08/27/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $30.00 | Research |
| Study: A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | ||||||
| 04/10/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $1,110.00 | Research |
| Study: A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN JAPANESE ADULT PARTICIPANTS WITH OBESITY DISEASE | ||||||
| 01/11/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $7,309.00 | Research |
| Study: A Randomized, Two-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded, Proof-of-concept Study Investigating the Efficacy, Safety and Tolerability of QUC398 in Patients With Symptomatic Knee Osteoarthritis | ||||||
| 01/11/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $6,724.00 | Research |
| Study: A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis | ||||||
| 01/11/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $2,480.00 | Research |
| Study: A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy | ||||||
| 01/11/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $1,830.00 | Research |
| Study: A Randomized, Placebo Controlled, Investigator and Participant-blinded Study Investigating Safety, Tolerability, and Efficacy of RHH646 in Participants With Knee Osteoarthritis | ||||||
| 01/11/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $1,020.00 | Research |
| Study: A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy | ||||||
| 01/11/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $720.00 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 IN ADULTS WITH MIXED DYSLIPIDEMIA | ||||||
| 01/11/2024 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $120.00 | Research |
| Study: A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-articular Canakinumab Followed by Intra-articular LNA043 in Patients With Knee Osteoarthritis | ||||||
| 10/16/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $630.00 | Research |
| Study: A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy | ||||||
| 09/19/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $510.00 | Research |
| Study: A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy | ||||||
| 07/11/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $4,170.00 | Research |
| Study: A Randomized, Placebo Controlled, Investigator and Participant-blinded Study Investigating Safety, Tolerability, and Efficacy of RHH646 in Participants With Knee Osteoarthritis | ||||||
| 06/14/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $90.00 | Research |
| Study: A randomized placebo controlled patient and investigator blinded Proof of Concept study investigating the safety tolerability and preliminary efficacy of multiple intra articular LNA043 injections in regenerating the articular cartilage of the knee in patients with articular cartilage lesions | ||||||
| 01/24/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $13,560.00 | Research |
| Study: A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-articular Canakinumab Followed by Intra-articular LNA043 in Patients With Knee Osteoarthritis | ||||||
| 01/24/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $13,260.00 | Research |
| Study: A Randomized, Two-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded, Proof-of-concept Study Investigating the Efficacy, Safety and Tolerability of QUC398 in Patients With Symptomatic Knee Osteoarthritis | ||||||
| 01/24/2023 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $9,300.00 | Research |
| Study: A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis | ||||||
| 01/24/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $2,640.00 | Research |
| Study: A PHASE 2 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 IN ADULTS WITH MIXED DYSLIPIDEMIA | ||||||
| 01/24/2023 | Eli Lilly and Company | — | — | Cash or cash equivalent | $870.00 | Research |
| Study: A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO IN PARTICIPANTS WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | ||||||
| 08/19/2022 | Novartis Pharmaceuticals Corporation | — | — | Cash or cash equivalent | $90.00 | Research |
| Study: AN OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY TOLERABILITY EFFICACY AND PHARMACOKINETICS OF CDZ173 IN PATIENTS WITH APDS PASLI ACTIVATED PHOSPHOINOSITIDE 3 KINASE DELTA SYNDROME P1108 ACTIVATING MUTATION CAUSING SENESCENT T CELLS LYMPHADE | ||||||
| 06/14/2022 | Eli Lilly and Company | — | — | Cash or cash equivalent | $120.00 | Research |
| Study: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 IN ADULTS WITH MIXED DYSLIPIDEMIA | ||||||
| 05/17/2022 | NOVARTIS PHARMACEUTICALS CORPORATION | — | — | Cash or cash equivalent | $90.00 | Research |
| Study: A REGISTRY STUDY OF CHINESE PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| MONARCH 2- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF FULVESTRANT WITH OR WITHOUT ABEMACICLIB, A CDK4 6 INHIBITOR, FOR WOMEN WITH HORMONE RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $24,773 | 2 |
| A RANDOMIZED PLACEBO CONTROLLED PATIENT AND INVESTIGATOR BLINDED PROOF OF CONCEPT STUDY INVESTIGATING THE SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF MULTIPLE INTRA ARTICULAR LNA043 INJECTIONS IN REGENERATING THE ARTICULAR CARTILAGE OF THE KNEE IN PAT | Novartis Pharmaceuticals Corporation | $23,625 | 3 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP PHASE II 24 WEEK STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF AIN457 IN PATIENTS WITH ACTIVE OVERUSE TENDINOPATHY REFRACTORY TO ORAL NSAIDS ACETAMINOPHEN PHYSIOTHERAPY OR CORTICOST | Novartis Pharmaceuticals Corporation | $22,950 | 2 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE 3 STUDY OF NONSTEROIDAL AROMATASE INHIBITORS -ANASTROZOLE OR LETROZOLE- PLUS LY2835219 A CDK4-6 INHIBITOR OR PLACEBO IN POSTMENOPAUSAL WOMEN WITH HORMONE RECEPTOR POSITIVE HER2-NEGATIVE LOCOREGIONALLY RECURRENT | Eli Lilly and Company | $21,525 | 2 |
| A Randomized, Two-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded, Proof-of-concept Study Investigating the Efficacy, Safety and Tolerability of QUC398 in Patients With Symptomatic Knee Osteoarthritis | Novartis Pharmaceuticals Corporation | $20,569 | 2 |
| A RANDOMIZED PLACEBO CONTROLLED PATIENT AND INVESTIGATOR BLINDED PROOF OF CONCEPT STUDY INVESTIGATING THE SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF MULTIPLE INTRA ARTICULAR LNA043 INJECTIONS IN REGENERATING THE ARTICULAR CARTILAGE OF THE KNEE IN PATIENTS WITH ARTICULAR CARTILAGE LESIONS | Novartis Pharmaceuticals Corporation | $18,600 | 1 |
| A RANDOMIZED DOUBLE BLIND MULTICENTER STUDY TO ASSESS THE SAFETY TOLERABILITY AND EFFICACY OF A COMBINATION TREATMENT OF TROPIFEXOR LJN452 AND CENICRIVIROC CVC IN ADULT PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND LIVER FIBROSIS | Novartis Pharmaceuticals Corporation | $17,400 | 1 |
| A Randomized, Two-arm, Placebo-controlled, Participant and Investigator-blinded Study Investigating the Efficacy, Safety and Tolerability of DFV890 in Patients With Symptomatic Knee Osteoarthritis | Novartis Pharmaceuticals Corporation | $16,024 | 2 |
| A PHASE 2 STUDY OF REGN2810, A FULLY HUMAN MONOCLONAL ANTIBODY TO PROGRAMMED DEATH-1 PD-1, IN PATIENTS WITH ADVANCED CUTANEOUS SQUAMOUS CELL CARCINOMA | Regeneron Pharmaceuticals, Inc. | $14,865 | 11 |
| A Multi site Randomized Placebo controlled Double blind Multiple Ascending Subcutaneous Dose Study to Evaluate the Safety Tolerability and Pharmacokinetics of BMS 986089 in Ambulatory Boys With Duchenne Muscular Dystrophy | E.R. Squibb & Sons, L.L.C. | $14,385 | 2 |
| A Randomized, Four-arm, Placebo-controlled, Participant, Investigator and Sponsor-blinded Study Investigating the Safety, Tolerability and Efficacy of Intra-articular Canakinumab Followed by Intra-articular LNA043 in Patients With Knee Osteoarthritis | Novartis Pharmaceuticals Corporation | $13,680 | 2 |
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY PHARMACOKINETICS AND EFFICACY OF INTRAVENOUS BIMAGRUMAB IN OBESE PATIENTS WITH TYPE 2 DIABETES | NOVARTIS PHARMACEUTICALS CORPORATION | $9,608 | 2 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 2 PART ADAPTIVE DESIGN MULTICENTER 12 WEEK STUDY TO ASSESS SAFETY TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPETATIS NASH | NOVARTIS PHARMACEUTICALS CORPORATION | $8,820 | 2 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED 2 PART ADAPTIVE DESIGN MULTICENTER 12 WEEK STUDY TO ASSESS SAFETY TOLERABILITY AND EFFICACY OF LJN452 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPETATIS NASH | Novartis Pharmaceuticals Corporation | $8,625 | 2 |
| A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP PHASE II 24 WEEK STUDY INVESTIGATING THE EFFICACY SAFETY AND TOLERABILITY OF AIN457 IN PATIENTS WITH ACTIVE OVERUSE TENDINOPATHY REFRACTORY TO ORAL NSAIDS ACETAMINOPHEN PHYSIOTHERAPY OR CORTICOSTEROID INJECTIONS | NOVARTIS PHARMACEUTICALS CORPORATION | $8,550 | 1 |
| MONARCHER-A PHASE 2, RANDOMIZED, MULTICENTER, 3-ARM, OPEN-LABEL STUDY TO COMPARE THE EFFICACY OF ABEMACICLIB PLUS TRASTUZUMAB WITH OR WITHOUT FULVESTRANT TO STANDARD-OF-CARE CHEMOTHERAPY OF PHYSICIANS CHOICE PLUS TRASTUZUMAB IN WOMEN WITH HR+, HER2+ LOCALLY ADVANCED OR METASTATIC BREAST CANCER | Eli Lilly and Company | $7,695 | 2 |
| PHASE I AND OR IIA 2PART MULTI CENTER SINGLE ARM OPEN LABEL STUDY TO DETERMINE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ORAL DABRAFENIB IN PEDIATRIC SUBJECTS AGED 1 MONTH TO LESS THAN 18 YEARS WITH ADVANCED BRAF V600 MUTATION POSITIVE SOLID TUMORS | Novartis Pharmaceuticals Corporation | $7,350 | 3 |
| EFFICACY AND SAFETY OF TIRZEPATIDE ONCE WEEKLY IN PARTICIPANTS WITHOUT TYPE 2 DIABETES WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT- RELATED COMORBIDITIES: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL (SURMOUNT-1) | Eli Lilly and Company | $7,231 | 2 |
| AN OPEN LABEL DOSE ESCALATION PHASE I AND OR II STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS PHARMACODYNAMICS AND CLINICAL ACTIVITY OF THE MEK INHIBITOR TRAMETINIB IN CHILDREN AND ADOLESCENTS SUBJECTS WITH CANCER OR PLEXIFORM NEUROFIBROMAS AND TRAMETI | Novartis Pharmaceuticals Corporation | $6,825 | 2 |
| A Randomized, Placebo Controlled, Investigator and Participant-blinded Study Investigating Safety, Tolerability, and Efficacy of RHH646 in Participants With Knee Osteoarthritis | Novartis Pharmaceuticals Corporation | $6,000 | 2 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PARTICIPANTS WITH TYPE 2 DIABETES | Eli Lilly and Company | $5,850 | 1 |
| A RANDOMIZED, TWO-ARM, PLACEBO-CONTROLLED, PARTICIPANT AND INVESTIGATOR-BLINDED STUDY INVESTIGATING THE EFFICACY, SAFETY AND TOLERABILITY OF DFV890 IN PATIENTS WITH SYMPTOMATIC KNEE OSTEOARTHRITIS | Novartis Pharmaceuticals Corporation | $5,385 | 2 |
| A randomized, parallel-group, 24 week, double-blind, placebo-controlled, multicenter Phase 3 study to assess the efficacy and safety of secukinumab compared to placebo in adult patients with active rotator cuff tendinopathy | Novartis Pharmaceuticals Corporation | $4,640 | 4 |
| A 28 WEEK RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED MULTI CENTER PARALLEL GROUP DOSE RANGE FINDING STUDY TO ASSESS THE EFFECT OF MONTHLY DOSES OF BIMAGRUMAB 70 210 AND 700 MG ON SKELETAL MUSCLE STRENGTH AND FUNCTION IN OLDER ADULTS WITH SARCOPENIA | NOVARTIS PHARMACEUTICALS CORPORATION | $4,463 | 2 |
| TRINITI1 A PHASE I AND OR II SINGLE ARM OPEN LABEL STUDY OF RIBOCICLIB IN COMBINATION WITH EVEROLIMUS PLUS EXEMESTANE IN THE TREATMENT OF MEN AND POSTMENOPAUSAL WOMEN WITH HR PLUS HER2 LOCALLY ADVANCED OR METASTATIC BREAST CANCER FOLLOWING PROGRESSION ON A CDK 4 AND OR 6 INHIBITOR | NOVARTIS PHARMACEUTICALS CORPORATION | $4,193 | 2 |
| A RANDOMIZED DOUBLE BLIND DOSE FINDING STUDY TO EVALUATE THE CHANGE IN WEIGHT AFTER 12 WEEKS TREATMENT WITH 4 DOSES OF LIK066 COMPARED TO PLACEBO IN JAPANESE PATIENTS WITH OBESITY DISEASE | NOVARTIS PHARMACEUTICALS CORPORATION | $4,043 | 1 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3437943 COMPARED WITH PLACEBO IN PARTICIPANTS WHO HAVE OBESITY OR ARE OVERWEIGHT WITH WEIGHT-RELATED COMORBIDITIES | Eli Lilly and Company | $3,990 | 2 |
| CT-P10 3.4 | Celltrion, Inc. | $3,825 | 5 |
| A RANDOMIZED PLACEBO CONTROLLED PATIENT AND INVESTIGATOR BLINDED PROOF OF CONCEPT STUDY INVESTIGATING THE SAFETY TOLERABILITY AND PRELIMINARY EFFICACY OF MULTIPLE INTRA ARTICULAR LNA043 INJECTIONS IN REGENERATING THE ARTICULAR CARTILAGE OF THE KNEE IN PATIENTS WITH ARTICULAR CARTILAGE LESIONS | NOVARTIS PHARMACEUTICALS CORPORATION | $3,780 | 1 |
| A Phase IIb Randomized Double Blind Placebo Controlled Parallel Group Multiple Dose Study to Evaluate the Safety Pk and PD effects of BMS 986036 in Adults with Nonalcoholic steato hepatitis | E.R. Squibb & Sons, L.L.C. | $3,570 | 3 |
| AN OPEN LABEL DOSE ESCALATION PHASE I AND OR II STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS PHARMACODYNAMICS AND CLINICAL ACTIVITY OF THE MEK INHIBITOR TRAMETINIB IN CHILDREN AND ADOLESCENTS SUBJECTS WITH CANCER OR PLEXIFORM NEUROFIBROMAS AND TRAMETINIB IN COMBINATION WITH DABRAFENIB IN CHILDREN AND ADOLESCENTS WITH CANCERS HARBORING V600 MUTATIONS | NOVARTIS PHARMACEUTICALS CORPORATION | $3,465 | 2 |
| A RANDOMIZED MULTI CENTRE DOUBLE BLIND PLACEBO CONTROLLED PHASE IIB TO EVALUATE THE SAFETY AND EFFICACY OF IV BYM338 ON FUNCTION MOBILITY AND FALL REDUCTION IN PATIENTS AFTER SURGICAL TREATMENT OF HIP FRACTURE | NOVARTIS PHARMACEUTICALS CORPORATION | $3,413 | 2 |
| A RANDOMIZED PHASE 2 STUDY OF LY2157299 VERSUS LY2157299 - SORAFENIB COMBINATION VERSUS SORAFENIB IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA | Eli Lilly and Company | $3,098 | 1 |
| PHASE I AND OR IIA 2PART MULTI CENTER SINGLE ARM OPEN LABEL STUDY TO DETERMINE THE SAFETY TOLERABILITY AND PHARMACOKINETICS OF ORAL DABRAFENIB IN PEDIATRIC SUBJECTS AGED 1 MONTH TO LESS THAN 18 YEARS WITH ADVANCED BRAF V600 MUTATION POSITIVE SOLID TUMORS | NOVARTIS PHARMACEUTICALS CORPORATION | $2,678 | 2 |
| A PHASE 2 RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 IN ADULTS WITH MIXED DYSLIPIDEMIA | Eli Lilly and Company | $2,640 | 1 |
| A RANDOMIZED, FOUR-ARM, PLACEBO-CONTROLLED, PARTICIPANT, INVESTIGATOR AND SPONSOR-BLINDED STUDY INVESTIGATING THE SAFETY, TOLERABILITY AND EFFICACY OF INTRA-ARTICULAR CANAKINUMAB FOLLOWED BY INTRA-ARTICULAR LNA043 IN PATIENTS WITH KNEE OSTEOARTHRITIS | Novartis Pharmaceuticals Corporation | $2,550 | 2 |
| A PHASE II STUDY OF THE BRAF INHIBITOR DABRAFENIB AS A SINGLE AGENT AND IN COMBINATION WITH THE MEK INHIBITOR TRAMETINIB IN SUBJECTS WITH BRAF V600E MUTATION POSITIVE METASTATIC STAGE IV NONSMALL CELL LUNG CANCER | NOVARTIS PHARMACEUTICALS CORPORATION | $2,100 | 2 |
| A RANDOMIZED SUBJECT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED STUDY TO ASSESS THE SAFETY PHARMACOKINETICS AND EFFICACY OF INTRAVENOUS BIMAGRUMAB IN OBESE PATIENTS WITH TYPE 2 DIABETES | Novartis Pharmaceuticals Corporation | $2,025 | 1 |
| A RANDOMIZED PATIENT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF LMB763 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPATITIS NASH | NOVARTIS PHARMACEUTICALS CORPORATION | $1,995 | 2 |
| LARGE PROSPECTIVE NATURAL HISTORY TRIAL IN SIBM PATIENTS | NOVARTIS PHARMACEUTICALS CORPORATION | $1,995 | 1 |
| MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY, AND EFFICACY OF IXEKIZUMAB IN PATIENTS FROM 6 TO LESS THAN 18 YEARS OF AGE WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS | Eli Lilly and Company | $1,890 | 2 |
| POC STUDY IN APDS ACTIVATED PI3K DELTA SYNDROME | Novartis Pharmaceuticals Corporation | $1,500 | 1 |
| A 28 WEEK RANDOMIZED WITHDRAWAL EXTENSION OF A DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS DURABILITY OF EFFECT ON SKELETAL MUSCLE STRENGTH AND FUNCTION UPON WITHDRAWAL OF BIMAGRUMAB 70 210 700 MG IN OLDER ADULTS WITH SARCOPENIA | NOVARTIS PHARMACEUTICALS CORPORATION | $1,388 | 2 |
| A PHASE II STUDY OF THE BRAF INHIBITOR DABRAFENIB AS A SINGLE AGENT AND IN COMBINATION WITH THE MEK INHIBITOR TRAMETINIB IN SUBJECTS WITH BRAF V600E MUTATION POSITIVE METASTATIC STAGE IV NONSMALL CELL LUNG CANCER | Novartis Pharmaceuticals Corporation | $1,200 | 3 |
| AN OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY TOLERABILITY EFFICACY AND PHARMACOKINETICS OF CDZ173 IN PATIENTS WITH APDS PASLI ACTIVATED PHOSPHOINOSITIDE 3 KINASE DELTA SYNDROME P1108 ACTIVATING MUTATION CAUSING SENESCENT T CELLS LYMPHADENOPATHY AND IMMUNODEFICIENCY | Novartis Pharmaceuticals Corporation | $1,200 | 2 |
| NASH EXPLORATORY SINGLE AND COMBINATION TREATMENT (NEXSCOT): AN OPEN LABEL, MULTICENTER, PLATFORM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF VARIOUS SINGLE AND COMBINATION TREATMENTS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) WHO MANIFEST A NON-ALCOHOLIC STEATOHEPATITIS (NASH)-LIKE BIOMARKER PHENOTYPE | Novartis Pharmaceuticals Corporation | $1,200 | 1 |
| A Phase I 2a Dose Escalation and Cohort Expansion Study of the Safety Tolerability and Efficacy of Anti LAG 3 Monoclonal Antibody BMS 986016 Administered Alone and in Combination With Anti PD 1 Monoclonal Antibody Nivolumab BMS 936558 in Advanced Solid Tu | E.R. Squibb & Sons, L.L.C. | $1,193 | 2 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE-DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN JAPANESE ADULT PARTICIPANTS WITH OBESITY DISEASE | Eli Lilly and Company | $1,110 | 1 |
| AN OPEN LABEL DOSE ESCALATION PHASE I AND OR II STUDY TO INVESTIGATE THE SAFETY PHARMACOKINETICS PHARMACODYNAMICS AND CLINICAL ACTIVITY OF THE MEK INHIBITOR TRAMETINIB IN CHILDREN AND ADOLESCENTS SUBJECTS WITH CANCER OR PLEXIFORM NEUROFIBROMAS AND TRAMETINIB IN COMBINATION WITH DABRAFENIB IN CHILDREN AND ADOLESCENTS WITH CANCERS HARBORING V600 MUTATIONS | Novartis Pharmaceuticals Corporation | $1,050 | 1 |
| A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3561774 IN ADULTS WITH MIXED DYSLIPIDEMIA | Eli Lilly and Company | $840.00 | 2 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND LIVER FIBROSIS | Novartis Pharmaceuticals Corporation | $825.00 | 1 |
| PHASE 2 STUDY WITH COMBINATION OF VEMURAFENIB WITH COBIMETINIB IN B-RAF V600E/K MUTATED MELANOMA PATIENTS TO NORMALIZE LDH AND OPTIMIZE NIVOLUMAB AND IPILIMUMAB THERAPY | Eli Lilly and Company | $825.00 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTER STUDY TO ASSESS EFFICACY, SAFETY, AND TOLERABILITY OF ORAL TROPIFEXOR (LJN452) & LICOGLIFLOZIN (LIK066) COMBINATION THERAPY, COMPARED TO EACH MONOTHERAPY, FOR TREATMENT OF ADULT PATIENTS WITH NONALCO | Novartis Pharmaceuticals Corporation | $510.00 | 1 |
| Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR ABL Tyrosine Kinase Inhibitor First Line Therapy in the United States | E.R. Squibb & Sons, L.L.C. | $472.50 | 2 |
| EMBER-3: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF LY3484356 VS INVESTIGATOR'S CHOICE OF ENDOCRINE THERAPY, IN PATIENTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE LOCALLY ADVANCED OR METASTATIC BREAST CANCER PREVIOUSLY TREATED WITH ENDOCRINE THERAPY | Eli Lilly and Company | $450.00 | 1 |
| AN OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY TOLERABILITY EFFICACY AND PHARMACOKINETICS OF CDZ173 IN PATIENTS WITH APDS PASLI ACTIVATED PHOSPHOINOSITIDE 3 KINASE DELTA SYNDROME P1108 ACTIVATING MUTATION CAUSING SENESCENT T CELLS LYMPHADENOPATHY AND IMMUNODEFICIENCY | NOVARTIS PHARMACEUTICALS CORPORATION | $367.50 | 1 |
| AN OPEN LABEL MULTI PART FIRST IN HUMAN STUDY OF ORAL LMI070 IN INFANTS WITH TYPE 1 SPINAL MUSCULAR ATROPHY | NOVARTIS PHARMACEUTICALS CORPORATION | $367.50 | 1 |
| A MULTI CENTER RANDOMIZED DOUBLE BLIND PARALLEL GROUP DOSE FINDING STUDY TO ASSESS THE EFFECT OF 3 DOSES OF LIK066 COMPARED TO PLACEBO OR EMPAGLIFLOZIN IN TYPE 2 DIABETES MELILTUS PATIENTS WITH HEART FAILURE | NOVARTIS PHARMACEUTICALS CORPORATION | $315.00 | 1 |
| A REGISTRY STUDY OF CHINESE PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) | Novartis Pharmaceuticals Corporation | $300.00 | 2 |
| A 12 WEEK RANDOMIZED PATIENT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY OF LIK066 IN OBESE PATIENTS WITH NON ALCOHOLIC STEATOHEPATITIS NASH | NOVARTIS PHARMACEUTICALS CORPORATION | $262.50 | 1 |
| A PHASE 2 STUDY OF LY2835219 FOR PATIENTS WITH PREVIOUSLY TREATED HORMONE RECEPTOR POSITIVE HER2 NEGATIVE METASTATIC BREAST CANCER | Eli Lilly and Company | $262.50 | 1 |
| A RANDOMIZED PATIENT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED MULTICENTER STUDY TO ASSESS THE SAFETY TOLERABILITY PHARMACOKINETICS AND EFFICACY OF LMB763 IN PATIENTS WITH NON ALCOHOLIC STEATOHEPATITIS NASH | Novartis Pharmaceuticals Corporation | $225.00 | 1 |
| A RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3437943 ONCE WEEKLY COMPARED TO PLACEBO IN PARTICIPANTS WITH SEVERE OBESITY AND ESTABLISHED CARDIOVASCULAR DISEASE | Eli Lilly and Company | $185.00 | 1 |
| NASH EXPLORATORY SINGLE AND COMBINATION TREATMENT (NEXSCOT): AN OPEN LABEL, MULTICENTER, PLATFORM STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF VARIOUS SINGLE AND COMBINATION TREATMENTS IN PATIENTS WITH NON-ALCOHOLIC FATTY L | Novartis Pharmaceuticals Corporation | $150.00 | 1 |
| A REGISTRY STUDY OF CHINESE PATIENTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) | NOVARTIS PHARMACEUTICALS CORPORATION | $90.00 | 1 |
| A randomized placebo controlled patient and investigator blinded Proof of Concept study investigating the safety tolerability and preliminary efficacy of multiple intra articular LNA043 injections in regenerating the articular cartilage of the knee in patients with articular cartilage lesions | Novartis Pharmaceuticals Corporation | $90.00 | 1 |
| AN OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY TOLERABILITY EFFICACY AND PHARMACOKINETICS OF CDZ173 IN PATIENTS WITH APDS PASLI ACTIVATED PHOSPHOINOSITIDE 3 KINASE DELTA SYNDROME P1108 ACTIVATING MUTATION CAUSING SENESCENT T CELLS LYMPHADE | Novartis Pharmaceuticals Corporation | $90.00 | 1 |
| A 12 WEEK RANDOMIZED PATIENT AND INVESTIGATOR BLINDED PLACEBO CONTROLLED PARALLEL GROUP STUDY TO INVESTIGATE THE EFFICACY OF LIK066 IN OBESE PATIENTS WITH NON ALCOHOLIC STEATOHEPATITIS NASH | Novartis Pharmaceuticals Corporation | $75.00 | 1 |
| A 28 WEEK RANDOMIZED WITHDRAWAL EXTENSION OF A DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO ASSESS DURABILITY OF EFFECT ON SKELETAL MUSCLE STRENGTH AND FUNCTION UPON WITHDRAWAL OF BIMAGRUMAB 70 210 700 MG IN OLDER ADULTS WITH SARCOPENIA | Novartis Pharmaceuticals Corporation | $75.00 | 1 |
| A RANDOMIZED, INVESTIGATOR AND SUBJECT BLINDED, MULTICENTER, PARALLEL-ARM STUDY TO DETERMINE THE SAFETY AND TOLERABILITY OF TROPIFEXOR | Novartis Pharmaceuticals Corporation | $75.00 | 1 |
| PHASE II OPEN LABEL GLOBAL STUDY TO EVALUATE THE EFFECT OF DABRAFENIB TREATMENT IN CHILDREN AND ADOLESCENT SUBJECTS WITH BRAF V600 MUTATION POSITIVE RELAPSED REFRACTORY OR PROGRESSIVE HGG TUMOR | Novartis Pharmaceuticals Corporation | $75.00 | 1 |
| A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT WITH WEIGHT RELATED COMORBIDITIES (ATTAIN-1) | Eli Lilly and Company | $30.00 | 1 |
About Dr. Robert Lorenzetti, MD
Dr. Robert Lorenzetti, MD is a Diagnostic Radiology healthcare provider based in Rochester, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/23/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356377311.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Lorenzetti, MD has received a total of $400,302 in payments from pharmaceutical and medical device companies, with $22,878 received in 2024. These payments were reported across 180 transactions from 6 companies. The most common payment nature is "" ($367,482).
Ad
Practice Information
- Specialty Diagnostic Radiology
- Location Rochester, NY
- Active Since 06/23/2006
- Last Updated 02/05/2009
- Taxonomy Code 2085R0202X
- Entity Type Individual
- NPI Number 1356377311
Products in Payments
- COSENTYX (Biological) $31,500
- BIMAGRUMAB (Biological) $22,965
- LNA043 (Drug) $19,830
- LJN452 (Drug) $17,520
- LIBTAYO CEMIPLIMAB-RWLC INJECTION (Biological) $14,865
- TAFINLAR (Drug) $13,403
- MEKINIST (Drug) $11,340
- LIK066 (Drug) $4,695
- KISQALI (Drug) $4,193
- LMB763 (Drug) $2,220
- TALTZ (Drug) $1,890
- SPRYCEL (Drug) $472.50
- CDZ173 (Biological) $367.50
- LMI070 (Drug) $367.50
- ADPT02A (Drug) $150.00
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Diagnostic Radiology Doctors in Rochester
David Kallmes, M.d, M.D
Diagnostic Radiology — Payments: $1.2M
Diagnostic Radiology $1.2M
Derace Schaffer, M.d, M.D
Diagnostic Radiology — Payments: $1.0M
Diagnostic Radiology $1.0M
Dr. Waleed Brinjikji, M.d, M.D
Diagnostic Radiology — Payments: $891,619
Diagnostic Radiology $891,619
Jonathan Morris, M.d, M.D
Diagnostic Radiology — Payments: $228,977
Diagnostic Radiology $228,977
Dr. Avice O'connell, M.d, M.D
Diagnostic Radiology — Payments: $213,742
Diagnostic Radiology $213,742
Devaraj Pyne, Md, Fsir, MD, FSIR
Diagnostic Radiology — Payments: $142,193
Diagnostic Radiology $142,193